Study Population.

<p>HCV DAA regimen stratification of the study population. A flow chart of the study population, stratifying by the type/combination of DAA regimens patients received. Abbreviations SOF: sofosbuvir; SMV: simeprevir; LDV: ledipasvir; RBV: ribavirin</p

Sustained Virologic Response.

<p>Overall sustained virologic response, stratified by stage of fibrosis. The graph indicates the number of patient who achieved undetectable HCV viral load at 12 weeks post-treatment. Of note, one patient had a negative HCV viral load measured at week 4 post-treatment and was counted towards achieving SVR.</p

Tacrolimus Trough Levels.

<p>Tacrolimus trough levels while on antiviral treatment. The chart demonstrates the trough level of tacrolimus on the sixteen patients receiving this agent, individually, at different treatment time points.</p

Hepatitis C Direct-Acting Antiviral.

<p>FDA approved direct-acting antiviral treatment for hepatitis C. HCV RNA is translated into a long polyprotein which consists of three structural proteins and seven non-structural (NS) proteins. The NS3/4A protease cleaves the downstream NS proteins into individual subunits. The major DAA classes consist of NS3/4A protease inhibitors, NS5A replication complex inhibitors and NS5B polymerase inhibitors.</p

Adverse Events Reported While on Treatment.

<p>Adverse Events Reported While on Treatment.</p